Dynamic DNA Laboratories
Reinforcing Personalized Medicine

It is a real eye-opener to know that adverse drug reactions (ADRs) contribute to over 100,000 deaths in the U.S. annually. Against the backdrop of having a highly medicated population, ADRs lead to 4.5 million emergency room visits a year and cost patients $3.5 billion annually, distressing both the patients and the hospital systems immensely. There is a glaring need for physicians to better understand their patients’ unique genetic profiles, which would allow the patients to feel better about the medications they take. Dynamic DNA Laboratories, a state-of-the-art genetics lab specializing in advanced DNA testing, is stepping up to the plate to help patients get control of their prescription medication and reduce or eliminate the role that “Trial and Error” has for long played in prescribing and dosing medications. Dynamic DNA’s primary areas of specialization is in molecular, cell and microbiology testing and research services coupled with expertise in creating high definition microscopic artwork and one-of-a-kind DNA portraits.

By looking at over 200 drug-gene interactions and taking into account current medications, dosages, and treatment guidance, the company empowers patients to understand themselves on a molecular level to make the optimal decisions for their health. Dynamic DNA works with one of the premier Pharmacogenomic Reporting companies to keep results as clear and concise as possible. The company is a member of various personalized medicine organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) in collaboration with St Jude Hospital, the Pharmacogenomics Research Network (PGRN), and STRIPE in collaboration with the American Society of Pharmacovigilance.

Having the most accurate, actionable information is the backbone of personalized medicine

“We ensure that everything we do is in conjunction with the most recent research to assure that we are doing as much as possible for our patients,” explains Austin O’Reilly, CEO of Dynamic DNA Laboratories.

A high technical knowledge combined with their family atmosphere is what helps Dynamic DNA shine brighter in the field of biotechnology and pharmacogenetics. As an owner and CEO who is well familiar with having a successful family business, O’Reilly has been able to translate that mindset and culture into the field of personalized medicine with Dynamic DNA. The Dynamic DNA team works hard for each other and its clients, treating each patient like family to ensure that they have the most amount of information possible to make the best decisions for their health.

“Having the most accurate, actionable information is the backbone of personalized medicine,” says O’Reilly. Once Dynamic DNA acquires that information, they focus on following all federal guidelines, including working with a patient’s physician in building up-to-date, application-driven solutions for patients no matter where they live or what their medication needs are. By being creative and flexible within the parameters of the often-changing field of personalized medicine, the company is able to build out processes to ensure that solutions are produced and delivered.

On that note, amid the COVID19 season, the company has experienced increased growth in their diagnostic testing department, enabling them to pivot their focus in expanding the capabilities of their diagnostics. They are working on their end-to-end logistics, which includes introducing a Laboratory Information Management System (LIMS) and beginning to incorporate it into their PGx reporting system.

With the firm belief that 2021 will be a big year for personalized medicine, Dynamic DNA will continue research to understand the implications that genomics has on drug-gene interactions. Dynamic DNA wants to continue to battle on the forefront of the COVID19 pandemic because they see the many lives they can change and save through personalized medicine.